Merck KgAA

Latest Headlines

Latest Headlines

Four years after a transatlantic slapdown, Merck KGaA will once again seek cladribine OK

Merck KGaA is bringing cladribine--the multiple sclerosis pill scuttled by regulatory rejections on both sides of the Atlantic four years ago--back from the dead.

Merck KGaA hustling a promising anti-malaria drug into human studies

Scientists in Scotland have been grabbing headlines with news that their preclinical research into an experimental single-dose antimalaria compound has shown real promise, spurring Merck KGaA to pick up the development and commercialization rights.

Merck KGaA says it can catch up in immuno-oncology with Pfizer's help

Merck KGaA, long plagued by clinical setbacks, is pushing into Phase III with a Pfizer-partnered cancer treatment, believing it can eventually catch up with rivals already on the market.

UPDATED: Merck KGaA forges a $941M CAR-T development deal with Intrexon

Four months after Pfizer stepped up with a $2.85 billion promise to partner with Merck KGaA on a preclinical PD-L1 oncology effort, the German pharma company has turned around to partner with Intrexon on an upstart CAR-T cancer drug development project.

Merck KGaA pitches in an extra $3M to support Opexa's PhIIb for MS

After gaining an option on Opexa's experimental drug for secondary progressive multiple sclerosis for only $5 million, Merck KGaA's Serono division has come up with an extra $3 million to support the biotech's ongoing Phase IIb study.

Ambitious cancer R&D plans may explain Merck KGaA cutbacks

Anyone looking for some perspective on Merck KGaA's recent R&D cutbacks should check out an interview CFO Marcus Kuhnert gave to CNBC. 

Ablynx gets caught in Merck KGaA's R&D retreat

A fast-changing Merck KGaA is backing away from discovery and preclinical R&D deals it set up with the antibody specialists at Ablynx. And the Belgian biotech saw its shares slide 14% today after news of the prospective breakup--included in Ablynx's annual summary--spread in the markets.

After painful odyssey, Newron wins European OK for Parkinson's add-on

More than three years after Merck KGaA decided to dump its partnership with Milan-based Newron Pharmaceuticals, which in turn iced a planned buyout by Biotie, the Italian biotech has persevered to win European approval to market safinamide as an add-on drug for Parkinson's disease.

UPDATED: Merck KGaA carves into MS R&D after a string of setbacks

After seeing its reputation as a leader in multiple sclerosis erode over recent years, Merck KGaA has decided to carve back the number of staffers working in preclinical R&D in the field.

Merck KGaA abandons Symphogen's cancer drug ahead of Phase III

Merck KGaA, in the process of paring down its pipeline, is walking away from a $625 million deal with Symphogen and handing back the company's lead asset, a targeted cancer treatment in midstage trials.